Lymphoma in rheumatoid arthritis: An immune system set up for failure

Arthritis and Rheumatism

Volumn 54, Issue 3, 2006, Pages 685-689

  Weyand, Cornelia M ^a   Goronzy, Jörg J ^a   Kurtin, Paul J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HLA DR4 ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DRUG EFFECT; EDITORIAL; GENE REARRANGEMENT; HAPLOTYPE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LEUKOCYTOCLASTIC VASCULITIS; LYMPHOMA; NONHODGKIN LYMPHOMA; ONCOGENE C MYC; ONCOGENE MYC; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTO ONCOGENE; RHEUMATOID ARTHRITIS; RISK FACTOR; SYNOVIUM; TISSUE INJURY;

ARTHRITIS, RHEUMATOID; HUMANS; LYMPHOMA;

EID: 33644926377     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21674     Document Type: Editorial

References (33)

1. Turesson C, Mattesen EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:206-11.
2. Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 2005;17:234-41.
3. De Maat MP, Trion A. C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol 2004;15:651-7.
4. De Boer OJ, Becker AE, van der Wal AC. T lymphocytes in atherogenesis: functional aspects and antigenic repertoire. Cardiovasc Res 2003;60:78-86.
5. Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002;29:1694-7.
6. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
7. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.
8. Franklin J, Lunt M, Bunn D, Symmons DP, Silman AJ. Incidence of lymphoma in a large primary-care derived cohort of inflammatory polyarthritis. Ann Rheum Dis 2005. E-pub ahead of print.
9. Imperato AK, Bingham CO III, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004;22 Suppl 35:8108-14.
10. Van Krieken JH. Lymphoproliferative disease associated with immune deficiency in children. Am J Clin Pathol 2004;122 Suppl: S122-7.
11. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-34.
12. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005;56:29-44.
13. Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005;5:415-30.
14. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
15. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
16. Ambinder RF. Epstein-Barr virus-associated lymphoproliferative disorders. Rev Clin Exp Hematol 2003;7:362-74.
17. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68.
18. Rossi D, Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology 2002;7:239-52.
19. Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr Opin Immunol 2005;17:468-75.
20. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003;31:145-55.
21. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003;17:785-820.
22. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115:3083-92.
23. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma develop-ment: twenty-six cases reported to the Food and Drug Adminis-tration. Arthritis Rheum 2002;46:3151-8.
24. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
25. Balandraud N, Roudier J, Roudier C. What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis? Semin Arthritis Rheum 2005;34 Suppl 1:31-3.
26. Callan MF. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 2004;16:399-405.
27. Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004;96:1691-702.
28. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 1998;95:14447-52.
29. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients' with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000;97:9203-8.
30. Salmon M, Akbar AN. Telomere erosion: a new link between HLA DR4 and rheumatoid arthritis? Trends Immunol 2004;25:339-41.
31. Schonland SO, Lopez C, Widmann T, Zimmer J, Bryl E, Goronzy JJ, et al. Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proc Natl Acad Sci U S A 2003;100:13471-6.
32. Weyand CM, Goronzy JJ. Stem cell aging and autoimmunity in rheumatoid arthritis. Trends Mol Med 2004;10:426-33.
33. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005;204:55-73.